All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2019-06-18T12:11:03.000Z

EHA 2019 | Recent advances in the field of allo-HSCT

By Emily Smith, Uwe Platzbecker
Featured
Uwe Platzbecker
Jun 18, 2019
Share:

Bookmark this article

At the 24th Congress of the European Hematology Association (EHA), Uwe Platzbecker from the University Hospital Leipzig, Leipzig, DE, discusses the recent advances in allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML). 

Prof. Plazbecker highlights two main issues with allo-HSCT. First is the risk of relapse following transplantation, and the second is the post-transplant risk of graft-versus-host disease (GvHD). Prof. Platzbecker discusses the recent advances to counteract these two issues, highlighting the use of minimal residual disease (MRD) status, measured by next generation sequencing (NGS), to assess a patient's risk of progression following allo-HSCT. He stated individual risk scores would likely be developed shortly, that are based on MRD levels and can guide treatment.
 
Additionally, Prof. Platzbecker explains that other ways of preventing relapse are the use of maintenance treatment and preemptive strategies. Preemptive approaches include measuring MRD rates post-transplant and treating at specified levels. The implementation of MRD in management pre- and post-transplant was described as the major current effort.
 
Finishing his discussion, Prof. Platzbecker talked about the treatment of GvHD, which is a threat for patients undergoing transplant. The approval of ruxolitinib, a JAK inhibitor, by the FDA for severe steroid refractory GvHD is one recent advance.

Recent advances in the field of allo-HSCT

More about...
Allo-HSCTEHA 2019Ruxolitinib

Your opinion matters

Do you intend to implement next-generation sequencing for measurable residual disease monitoring in MDS patients?
1 vote - 4 days left ...

Related articles

Add bookmark

Uwe Platzbecker | EHA 2018 |  What are the latest treatment management strategies for patients with APL?

Uwe Platzbecker Carl Gustav Carus University Hosptial, Dresden, DE Interview topic: What are the latest treatment management strategies for...

Jun 20, 2018
Add bookmark

Uwe Platzbecker | EHA 2018 |  What are the latest treatment management strategies for patients with APL?

Uwe Platzbecker Carl Gustav Carus University Hosptial, Dresden, DE Interview topic: What are...

Jun 20, 2018
Add bookmark

Prof. Uwe Platzbecker | ASH 2016 | 2nd line treatment after ATO + ATRA combination

Dr Uwe Platzbecker talks about possible 2nd line treatment options for patients that might relapse after first line treatment with ATO + ATRA combination.

Dec 15, 2016
Add bookmark

Prof. Uwe Platzbecker | ASH 2016 | 2nd line treatment after ATO + ATRA combination

Dr Uwe Platzbecker talks about possible 2nd line treatment options for patients that might relapse after first line...

Dec 15, 2016

Newsletter

Subscribe to get the best content related to AML delivered to your inbox